Study summary

The purpose of the study is to assess the safety of repeated applications of QUTENZA in reducing pain intensity in subjects who have peripheral neuropathic pain due to diabetes.

Additional Study Details

Phase
Phase 3
Product
  • QUTENZA
  • Type
    Interventional
    Masking
    Single (Outcomes Assessor)
    Enrollment number
    468
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site: 601
      Bonheiden, Belgium, 2820
      Withdrawn
      Site: 603
      Reet, Belgium, 2840
      Completed
      Site: 903
      Beroun, Czech Republic, 26601
      Completed
      Site: 910
      Brno, Czech Republic, 60200
      Completed
      Site: 908
      Chocen, Czech Republic, 56501
      Withdrawn
      Site: 907
      Hodonin, Czech Republic, 69501
      Completed
      Site: 911
      Litomerice, Czech Republic, 41201
      Withdrawn
      Site: 905
      Ostrava, Czech Republic, 70200
      Completed
      Site: 906
      Ostrava, Czech Republic, 71000
      Completed
      Site: 904
      Policka, Czech Republic, 57201
      Completed
      Site: 901
      Praha 4, Czech Republic, 14000
      Completed
      Site: 902
      Prerov, Czech Republic, 75003
      Completed
      Site: 909
      Rychnov nad Kneznou, Czech Republic, 51601
      Completed
      Site: 207
      Bron, France, 69677
      Completed
      Site: 202
      Paris, France, 75004
      Completed
      Site: 201
      Pierre Benite, France, 69495
      Completed
      Site: 206
      Toulouse, France, 31059
      Withdrawn
      Site: 511
      Bad Lauterberg, Germany, 37431
      Completed
      Site: 508
      Chiemsee, Germany, 83209
      Completed
      Site: 502
      Dresden, Germany, 1307
      Completed
      Site: 501
      Falkensee, Germany, 14612
      Completed
      Site: 514
      Frankfurt, Germany, 60311
      Terminated
      Site: 507
      Hamburg, Germany, 22177
      Completed
      Site: 509
      Koln, Germany, 50937
      Completed
      Site: 505
      Leipzig, Germany, 04109
      Completed
      Site: 506
      Muenster, Germany, 48145
      Withdrawn
      Site: 504
      Regensburg, Germany, 93053
      Completed
      Site: 512
      Wangen, Germany, 88239
      Completed
      Site: 404
      Milano, Italy, 20162
      Withdrawn
      Site: 407
      Milano, Italy, 20159
      Completed
      Site: 401
      Roma, Italy, 00133
      Withdrawn
      Site: 403
      Roma, Italy, 00133
      Completed
      Site: 651
      Utrecht, Netherlands, 3584 CX
      Withdrawn
      Site: 652
      Utrecht, Netherlands, 2333 ZA
      Completed
      Site: 965
      Bialystok, Poland, 15435
      Completed
      Site: 961
      Bydgoszcz, Poland, 85822
      Completed
      Site: 957
      Elblag, Poland, 82300
      Completed
      Site: 958
      Gdynia, Poland, 81049
      Completed
      Site: 954
      Katowice, Poland, 40954
      Completed
      Site: 964
      Krakow, Poland, 31530
      Completed
      Site: 951
      Lodz, Poland, 90153
      Completed
      Site: 966
      Lubin, Poland, 59300
      Completed
      Site: 953
      Poznan, Poland, 61655
      Completed
      Site: 959
      Torun, Poland, 87100
      Completed
      Site: 960
      Warszawa, Poland, 1868
      Withdrawn
      Site: 963
      Warszawa, Poland, 02256
      Completed
      Site: 714
      Kemerovo, Russian Federation, 150062
      Withdrawn
      Site: 707
      Moscow, Russian Federation, 79117778999
      Withdrawn
      Site: 712
      Nizhny Novgorod, Russian Federation, 79117778999
      Completed
      Site: 708
      Samara, Russian Federation, 79117778999
      Completed
      Site: 709
      Saratov, Russian Federation, 79117120826
      Withdrawn
      Site: 701
      St. Petersburg, Russian Federation, 79117120826
      Withdrawn
      Site: 702
      St. Petersburg, Russian Federation, 791177120826
      Completed
      Site: 703
      St. Petersburg, Russian Federation, 191015
      Completed
      Site: 704
      St. Petersburg, Russian Federation, 79117120826
      Completed
      Site: 706
      St. Petersburg, Russian Federation, 79117778999
      Withdrawn
      Site: 710
      St. Petersburg, Russian Federation, 79117778999
      Completed
      Site: 716
      St. Petersburg, Russian Federation, 194358
      Completed
      Site: 713
      Tomsk, Russian Federation, 79117778999
      Completed
      Site: 711
      Yaroslavl, Russian Federation, 79117778999
      Withdrawn
      Site: 302
      Cadiz, Spain, 11009
      Withdrawn
      Site: 301
      Toledo, Spain, 45004
      Completed
      Site: 303
      Valencia, Spain, 46010
      Completed
      Site: 304
      Valencia, Spain, 46014
      Completed
      Site: 305
      Valladolid, Spain, 47012
      Completed
      Site: 808
      Chernihiv, Ukraine, 14034
      Withdrawn
      Site: 809
      Dnipropetrovs'k, Ukraine, 49023
      Completed
      Site: 803
      Kharkiv, Ukraine, 61037
      Completed
      Site: 812
      Kvuv, Ukraine, 79010
      Completed
      Site: 805
      Kyiv, Ukraine, 2091
      Completed
      Site: 806
      Kyiv, Ukraine, 4114
      Completed
      Site: 807
      Kyiv, Ukraine, 4053
      Completed
      Site: 810
      Lviv, Ukraine, 79010
      Completed
      Site: 802
      Mykolayiv, Ukraine, 54003
      Completed
      Site: 801
      Odesa, Ukraine, 65009
      Withdrawn
      Site: 804
      Poltava, Ukraine, 36024
      Completed
      Site: 813
      Vinnitsa, Ukraine, 21010
      Completed
      Site: 815
      Zaporizhzhya, Ukraine, 69001
      Completed
      Site: 102
      Chorley, United Kingdom, PR7 1PP
      Completed
      Site: 103
      Liverpool, United Kingdom, L7 8XP
      Completed
      Site: 104
      Poole, United Kingdom, BH15 2JB
      Terminated
      Site: 101
      Rugby, United Kingdom, CV22 5PX

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?